Clinical Scorecard: Comparative Analysis of Baseline and On-Treatment Heart Failure with Preserved Ejection Fraction (HFpEF) in a Cardio-Oncology Setting: Observational Study on Cardiovascular Toxicity Associated with Cancer Therapies and Its Clinical Implications

At a Glance

Key Highlights

• 5.4% of cancer patients had known HFpEF prior to treatment initiation.
• Pre-existing HFpEF associated with higher mortality (27.8% vs. 12.8%).
• 14.4% of patients developed HFpEF events after cancer therapy initiation.
• Older age, female sex, arterial hypertension, and previous arrhythmias predicted HFpEF events.
• Current guidelines do not include HFpEF in CTRCD definitions.
• Adaptation of cancer therapy was necessary in 12.5% of patients who developed HFpEF events.

Guideline-Based Recommendations

Diagnosis

• Baseline cardiovascular evaluation recommended prior to cancer treatment initiation.

Management

• Adaptation of cancer therapy may be required for patients developing HFpEF events.

Monitoring & Follow-up

• On-treatment surveillance and long-term follow-up after treatment completion are essential.
• Integrate HFpEF in risk stratification tools.

Risks

• Pre-existing HFpEF is not included as a distinct risk factor for CTR-CVT in most risk stratification tools.

Patient & Prescribing Data

665 cancer patients, mean age 62.1 years, 54.1% female.

Cancer therapy adaptation was necessary in 12.5% of patients who developed HFpEF events.

Clinical Best Practices

• Utilize established risk scores for assessing cardiovascular risk in cancer patients.
• Consider HFpEF in risk stratification for cancer therapy-related cardiovascular toxicity.
• Monitor HFpEF closely in patients undergoing cancer therapy.

Related Resources & Content

• Study on HFpEF prevalence in cancer patients